Howard Oremland, RPh, MBA; Lauren G. Gallagher, MPH; John Schlie, PharmD; Dick Creager, MD, MPA; Anthony Palmieri, PharmD, MBA; Olga S. Matlin, PhD; and Steven M. Kymes, PhD
The authors examined trends in the utilization of prescription opioid medication following introduction of abuse deterrent technology for Oxycontin.
Jan E. Berger, MD, MJ—Editor-in-Chief
To achieve the triple aim, the healthcare benefit and the pharmacy benefit must evolve.
Sharon J. Rolnick, PhD, MPH; Steve Asche, MA; Pamala A. Pawloski, PharmD; Richard J. Bruzek, PharmD; and Brita Hedblom, BS
This study reports on barriers to and facilitators of medication adherence for asthma and diabetes patients who were both adherent and nonadherent to their medication regimen.
Myrl Weinberg, FASAE, CAE
People with chronic conditions need effective and affordable drugs to live longer and better lives. Unfortunately, regulations covering plans in state exchanges may impede access.
John A. Thompson, MD
This review presents data on ipilimumab and vemurafenib, 2 new targeted agents recently approved for the treatment of metastatic melanoma.
Lori Wetmore, PharmD, BCPS; William N. Kelly, PharmD; and John F. Trowbridge, MD, CPE
This article reviews current drug therapies for heart failure and therapy integration into a patient care framework improving patient adherence, quality of life, and decreased risk of readmission to acute care facilities.
Chris M. Kozma, PhD; Terra l. Slaton, MS; Wing Chow, PharmD, MPH; and Marcia F. T. Rupnow, PhD
This analysis of more than 50,000 patients examined medication use (anticonvulsants, opioids, and antidepressants) for diabetic peripheral neuropathy.
Guneet K. Jasuja, PhD; Shalender Bhasin, MD; Joel I. Reisman, AB; and Adam J. Rose, MD, MSc
Veterans Health Administration sites vary widely in rates of prescription of exogenous testosterone therapy for male veterans, even after adjusting for each site’s age profile.
Anju Parthan, PhD; Nicholas P. Emptage, MAE; Douglas C. A. Taylor, MBA; Hema N. Viswanathan, PhD; Nicole Yurgin, PhD; Bradley Stolshek, PharmD; Karen M. Clements, ScD; Charles Y. Tao, MA; and Milton C. Weinstein, PhD
Denosumab for osteoporosis in postmenopausal women at high risk for fracture results in minimal budgetary impact to a health plan over 3 years.